Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $15.10M by Medicaid between Jan 2018 and Dec 2024, across 234 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
ANTIOCH, CA 94531
ANTIOCH, CA 94531
33aNPI1851417547assigned 03/22/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.10M
24GClaims881,147
24DCodes billed234
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#147 of 410
Median peer was paid$6.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,328 | $364K | |
| 2019 | 96,195 | $719K | |
| 2020 | 84,174 | $823K | |
| 2021 | 127,374 | $1.10M | |
| 2022 | 153,991 | $1.34M | |
| 2023 | 175,707 | $1.29M | |
| 2024incomplete | 200,378 | $9.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 12,298 | 11,432 | $2.27M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 19,467 | 18,500 | $1.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.4% | 9,539 | 9,179 | $1.27M |
| 0450 | Emergency room services | 7.1% | 30,361 | 27,185 | $1.08M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 3,160 | 2,990 | $806K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 4,934 | 4,854 | $784K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.6% | 16,883 | 16,125 | $698K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.4% | 9,011 | 8,744 | $516K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 6,413 | 6,199 | $331K |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 11,078 | 10,819 | $308K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 9,075 | 8,197 | $187K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,276 | 2,244 | $160K |
222 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 16,979 | $151K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,873 | $142K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,874 | $141K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,382 | $139K |
| 0270 | <1% | 4,142 | $118K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,496 | $114K |
| G0378 | Hospital observation service, per hour | <1% | 1,928 | $114K |
| 99199 | Unlisted special service, procedure or report | <1% | 2,131 | $111K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,312 | $110K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,420 | $108K |
| 73630 | <1% | 4,759 | $102K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,447 | $101K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,506 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,508 | $92K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,240 | $91K |
| 80051 | <1% | 29,676 | $84K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 990 | $83K |
| 73610 | <1% | 3,512 | $82K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,082 | $80K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 408 | $79K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,300 | $76K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 507 | $75K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,262 | $74K |
| 73030 | <1% | 2,861 | $72K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 914 | $70K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,553 | $70K |
| 73564 | <1% | 1,830 | $69K | |
| J3490 | Unclassified drugs | <1% | 12,423 | $68K |
| 73560 | <1% | 2,735 | $63K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,432 | $60K |
| 82565 | <1% | 33,166 | $59K | |
| 74018 | <1% | 2,312 | $58K | |
| 73110 | <1% | 2,692 | $58K | |
| 73130 | <1% | 3,000 | $58K | |
| 72100 | <1% | 1,946 | $57K | |
| 83880 | <1% | 5,092 | $51K | |
| 93971 | <1% | 1,102 | $50K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,442 | $47K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,443 | $47K |
| 83690 | <1% | 17,177 | $47K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,988 | $44K |
| 82947 | <1% | 30,132 | $43K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,497 | $43K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,423 | $42K |
| 84520 | <1% | 29,761 | $42K | |
| 84484 | <1% | 9,912 | $42K | |
| 86900 | <1% | 3,040 | $41K | |
| 84460 | <1% | 21,207 | $40K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,026 | $39K |
| 73502 | <1% | 1,280 | $39K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 429 | $38K |
| 82247 | <1% | 21,759 | $37K | |
| 84450 | <1% | 19,816 | $37K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,389 | $37K |
| 84075 | <1% | 18,141 | $34K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 572 | $33K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,779 | $31K |
| 73080 | <1% | 1,312 | $30K | |
| 71250 | <1% | 385 | $26K | |
| 76857 | <1% | 378 | $25K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 130 | $24K |
| 84702 | <1% | 4,703 | $24K | |
| 87040 | <1% | 3,538 | $24K | |
| 70486 | <1% | 317 | $24K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,308 | $24K |
| 72040 | <1% | 778 | $23K | |
| 73140 | <1% | 1,364 | $23K | |
| 76770 | <1% | 552 | $22K | |
| 81001 | <1% | 22,688 | $21K | |
| 84703 | <1% | 8,441 | $21K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,938 | $21K |
| 87631 | <1% | 623 | $21K | |
| 83605 | <1% | 4,298 | $20K | |
| 83735 | <1% | 8,236 | $19K | |
| 73590 | <1% | 773 | $19K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,897 | $19K |
| 80306 | <1% | 2,193 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,251 | $18K |
| 74022 | <1% | 357 | $18K | |
| 86850 | <1% | 2,531 | $17K | |
| 93976 | <1% | 348 | $16K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 234 | $16K |
| 70491 | <1% | 108 | $16K | |
| 82077 | <1% | 2,274 | $15K | |
| 86901 | <1% | 3,040 | $14K | |
| 71101 | <1% | 202 | $14K | |
| 73562 | <1% | 566 | $14K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,305 | $14K |
| 87088 | <1% | 5,098 | $13K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,265 | $12K |
| 36430 | <1% | 349 | $11K | |
| 77080 | <1% | 378 | $10K | |
| 81003 | <1% | 14,707 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,202 | $9K |
| 72141 | <1% | 104 | $9K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,599 | $9K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,574 | $8K |
| 76536 | <1% | 153 | $8K | |
| 85610 | <1% | 6,638 | $8K | |
| 72070 | <1% | 118 | $8K | |
| 93970 | <1% | 113 | $8K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 852 | $8K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,423 | $8K |
| 82962 | <1% | 5,434 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 498 | $7K |
| 80179 | <1% | 1,082 | $7K | |
| 73522 | <1% | 54 | $7K | |
| 84100 | <1% | 4,284 | $7K | |
| 85379 | <1% | 2,118 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,674 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 706 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 224 | $6K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 339 | $6K |
| 59025 | Fetal non-stress test | <1% | 610 | $6K |
| 73090 | <1% | 401 | $5K | |
| 85652 | <1% | 6,645 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,084 | $5K |
| 73552 | <1% | 69 | $5K | |
| 82803 | <1% | 789 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 142 | $4K |
| 0710 | <1% | 1,786 | $4K | |
| 82248 | <1% | 2,228 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $4K |
| 0250 | <1% | 13,422 | $4K | |
| 85027 | <1% | 2,139 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,755 | $3K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 770 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,115 | $3K |
| 85378 | <1% | 1,064 | $3K | |
| 96376 | <1% | 1,883 | $3K | |
| 86140 | <1% | 1,529 | $3K | |
| 73060 | <1% | 38 | $3K | |
| 73660 | <1% | 130 | $3K | |
| 70496 | <1% | 12 | $3K | |
| 84132 | <1% | 1,736 | $2K | |
| 90715 | <1% | 102 | $2K | |
| 76870 | <1% | 54 | $2K | |
| Z7502 | <1% | 336 | $2K | |
| 72170 | <1% | 13 | $2K | |
| 82550 | <1% | 647 | $2K | |
| 0272 | <1% | 226 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 451 | $1K |
| 87210 | <1% | 566 | $1K | |
| 87070 | <1% | 385 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 523 | $1K |
| 82310 | <1% | 806 | $1K | |
| 73221 | <1% | 12 | $1K | |
| 82570 | <1% | 374 | $908.15 | |
| 12001 | <1% | 195 | $886.42 | |
| 99070 | <1% | 77 | $830.04 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 802 | $827.18 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 119 | $806.43 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,269 | $803.64 |
| 0637 | <1% | 43,311 | $802.50 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,038 | $591.93 |
| 84156 | <1% | 323 | $523.63 | |
| 87324 | <1% | 74 | $510.75 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13 | $497.10 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 157 | $495.01 |
| 87449 | <1% | 85 | $495.00 | |
| 84295 | <1% | 206 | $492.02 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 36 | $401.46 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 13 | $363.52 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 96 | $338.87 |
| 83615 | <1% | 237 | $328.39 | |
| 12011 | <1% | 53 | $306.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 254 | $289.25 |
| 85730 | <1% | 116 | $260.90 | |
| 87081 | <1% | 123 | $228.96 | |
| 0370 | <1% | 1,562 | $189.50 | |
| 85008 | <1% | 903 | $185.23 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 72 | $184.79 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 129 | $179.29 |
| 0636 | <1% | 126 | $176.43 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 55 | $161.17 |
| 85007 | <1% | 292 | $160.30 | |
| 29125 | <1% | 70 | $102.17 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 29 | $101.01 |
| 86780 | <1% | 56 | $94.40 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 32 | $88.98 |
| 84550 | <1% | 40 | $88.39 | |
| 82040 | <1% | 94 | $84.22 | |
| 96367 | <1% | 31 | $78.74 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 61 | $74.61 |
| 82140 | <1% | 13 | $55.90 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 97 | $55.48 |
| 87205 | <1% | 41 | $31.92 | |
| 88304 | <1% | 27 | $24.40 | |
| 82150 | <1% | 13 | $24.19 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 287 | $23.01 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 651 | $18.31 |
| 80061 | Lipid panel | <1% | 46 | $11.54 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 66 | $9.37 |
| 80329 | <1% | 77 | $5.00 | |
| 80320 | <1% | 184 | $5.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 89 | $4.76 |
| 82272 | <1% | 13 | $2.56 | |
| 80325 | 0% | 71 | $0.00 | |
| 90749 | 0% | 212 | $0.00 | |
| 76376 | 0% | 252 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 109 | $0.00 |
| 82465 | 0% | 20 | $0.00 | |
| 0002A | 0% | 34 | $0.00 | |
| 82374 | 0% | 26 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 15 | $0.00 |
| 83718 | 0% | 18 | $0.00 | |
| 83540 | 0% | 21 | $0.00 | |
| 83721 | 0% | 32 | $0.00 | |
| 80349 | 0% | 446 | $0.00 | |
| 87340 | 0% | 32 | $0.00 | |
| 82043 | 0% | 52 | $0.00 | |
| 0001A | 0% | 38 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 12 | $0.00 |
| 82728 | 0% | 31 | $0.00 | |
| 82435 | 0% | 26 | $0.00 | |
| 0410 | 0% | 18 | $0.00 | |
| Z7610 | 0% | 48 | $0.00 | |
| 86803 | 0% | 22 | $0.00 | |
| 0258 | 0% | 384 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 31 | $0.00 |
| 82607 | 0% | 14 | $0.00 | |
| 83550 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKEOWN, COLLEEN (SENIOR VICE PRESIDENT, AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Walnut Creek, CA | $8.70M |
| Kaiser Foundation Hospitals | Martinez, CA | $604K |
| Kaiser Foundation Hospitals | Martinez, CA | $438K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.